Product Description
Mechanisms of Action: DNA Adduct
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical, Nasal, Intramuscular
FDA Designation: *
Approval Status: Approved
Approved Countries: Denmark | European Medicines Agency | Finland | Iceland | Ireland | Lithuania | Pakistan | Peru | Poland | Turkey | United States
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Influenza, Human
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2016-004753-33 | P3 |
Active, not recruiting |
Influenza, Human |
2018-09-21 |
2025-06-29 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/17/2023 |
News Article |
CSL Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2023/24 U.S. Season |
|
07/11/2022 |
News Article |
Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2022/23 U.S. Season |
|
01/04/2022 |
News Article |
United States Vaccines Market 2021 Growth Factors, Product Overview, Segmentation and Forecast Study to 2027 |
|
01/04/2022 |
News Article |
Flu Vaccine Market 2021 Status and Outlook, Industry Growth Rate, Opportunities and Challenges to 2025 |